Effect of Natalizumab on sNfL and sGFAP Levels in Multiple Sclerosis Patients
Raquel Sainz-Amo(Instituto de Salud Carlos III), Luisa María Villar(Evidence (Italy)), Enric Monreal(Hospital Universitario Ramón y Cajal), José Ignacio Fernández-Velasco(Hospital Universitario Ramón y Cajal), Alexander Rodero-Romero(Universidad de Alcalá), Noelia Villarrubia(Universidad de Alcalá), Fernando Rodríguez‐Jorge(Universidad de Alcalá), Lucienne Costa‐Frossard(Universidad de Alcalá), Jaime Masjuán(Universidad de Alcalá), José Luís Veiga-González(Instituto de Salud Carlos III), Juan Luis Chico‐García(Universidad de Alcalá)
Cited by 10
Related Papers
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source
|New England Journal of Medicine|2019|823
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
|JAMA|2021|728
Acute‐onset smell and taste disorders in the context of COVID‐19: a pilot multicentre polymerase chain reaction based case–control study
|European Journal of Neurology|2020|385